BioLinqPRIVATE · FOUNDED 2010
CalyxoPRIVATE · FOUNDED 2016Each bar is the last disclosed mark — $400M for BioLinq (post-money, Apr 2025) and $684.6M for Calyxo (basis undisclosed, Apr 2026).
BioLinqPRIVATEHealth · US · 2010CalyxoPRIVATEHealth · US · 2016The $400M tells you…The $684.6M tells you…At least one valuation basis is undisclosed, so the two numbers stay side by side, each with its own chip, and no ratio is scored. Both are private: there is no public quote and no Canborsa market on either name.
BioLinq's sector is Medical Devices / Biotech; Calyxo's sector is Medical Devices.
BioLinq was last valued at $400M in April 2025, and Calyxo at $684.6M in April 2026.
BioLinq raised $100M through its Series C round in April 2025, while Calyxo raised $40M through its Series F round in April 2026.
BioLinq's lead investors include Alpha Wave Ventures, and Calyxo's include Ally Bridge Group and Janus Henderson Investors.
BioLinq launched in 2010; Calyxo launched in 2016.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
